[Skip to Navigation]
Editorial
November 15, 2020

Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events: What Matters Most: the Drug, the Dose, or the Placebo?

Author Affiliations
  • 1Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA. 2020;324(22):2262-2264. doi:10.1001/jama.2020.22387

Hypertriglyceridemia is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), independent of low-density lipoprotein cholesterol (LDL-C) control.1 Standard treatment strategies have included lifestyle modification, weight and diabetes management, and statin therapy. Previous triglyceride-lowering trials with niacin, fibrates, and mixed omega-3 fatty acids have not demonstrated consistent risk reduction of ASCVD.1,2 However, strong evidence has recently emerged for the role of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in its highly purified ethyl ester derivative, icosapent ethyl (IPE), in addition to statin treatment, for ASCVD risk reduction.1,2

×